← Back to Screener
Bicycle Therapeutics plc American Depositary Shares (BCYC)
Price$5.29
Favorite Metrics
Price vs S&P 500 (26W)-44.68%
Price vs S&P 500 (4W)13.04%
Market Capitalization$369.73M
All Metrics
Book Value / Share (Quarterly)$8.79
P/TBV (Annual)2.17x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)71.22%
Cash Flow / Share (Quarterly)$-3.63
Price vs S&P 500 (YTD)-28.86%
Net Profit Margin (TTM)-301.66%
EPS (TTM)$-3.16
10-Day Avg Trading Volume0.41M
EPS Excl Extra (TTM)$-3.16
Revenue Growth (5Y)47.52%
EPS (Annual)$-3.16
ROI (Annual)-35.85%
Net Profit Margin (5Y Avg)-560.24%
Cash / Share (Quarterly)$9.05
Revenue Growth QoQ (YoY)1193.28%
ROA (Last FY)-30.51%
Revenue Growth TTM (YoY)105.77%
EBITD / Share (TTM)$-3.48
ROE (5Y Avg)-33.37%
Operating Margin (TTM)-340.38%
Cash Flow / Share (Annual)$-3.63
P/B Ratio0.61x
P/B Ratio (Quarterly)0.77x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-3.55x
Net Interest Coverage (TTM)-26.39x
ROA (TTM)-27.39%
EPS Incl Extra (Annual)$-3.16
Current Ratio (Annual)11.98x
Quick Ratio (Quarterly)11.66x
3-Month Avg Trading Volume0.39M
52-Week Price Return-28.84%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)5.09x
Asset Turnover (Annual)0.10x
52-Week High$9.55
Operating Margin (5Y Avg)-599.41%
EPS Excl Extra (Annual)$-3.16
CapEx CAGR (5Y)14.39%
Tangible BV CAGR (5Y)40.61%
26-Week Price Return-35.94%
Quick Ratio (Annual)11.66x
13-Week Price Return-19.49%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.98x
Enterprise Value$-257.505
Revenue / Share Growth (5Y)14.06%
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)14.21%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-301.45%
Cash / Share (Annual)$9.05
3-Month Return Std Dev56.06%
Net Income / Employee (TTM)$-1
ROE (Last FY)-35.90%
Net Interest Coverage (Annual)-28.94x
EPS Basic Excl Extra (Annual)$-3.16
Receivables Turnover (TTM)378.26x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)26.98x
ROI (TTM)-33.16%
P/S Ratio (TTM)5.09x
Pretax Margin (5Y Avg)-566.76%
Revenue / Share (Annual)$1.05
Tangible BV / Share (Annual)$9.06
Price vs S&P 500 (52W)-63.93%
Year-to-Date Return-24.72%
5-Day Price Return7.03%
EPS Normalized (Annual)$-3.16
ROA (5Y Avg)-23.98%
Net Profit Margin (Annual)-301.66%
Month-to-Date Return14.87%
Cash Flow / Share (TTM)$-4.79
EBITD / Share (Annual)$-3.48
Operating Margin (Annual)-340.38%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-31.47%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.16
P/TBV (Quarterly)1.41x
P/B Ratio (Annual)0.77x
Pretax Margin (TTM)-301.45%
Book Value / Share (Annual)$8.79
Price vs S&P 500 (13W)-22.35%
Beta1.68x
Revenue / Share (TTM)$1.05
ROE (TTM)-33.20%
52-Week Low$4.24
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCYCBicycle Therapeutics plc American Depositary Shares | 5.09x | 105.77% | — | — | $5.29 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing Bicycles, a novel class of constrained synthetic peptides designed to selectively target cancer cells. Its lead candidate, BT1718, combines a Bicycle targeting moiety with a tumor-killing toxin for oncology indications with high unmet medical needs. The company operates in the United States and United Kingdom.